

# Predictors of In-Stent Restenosis

Mehmet Kadri Akboga, MD<sup>1</sup>  and Samet Yilmaz, MD<sup>2</sup> 

Angiology  
2019, Vol. 70(3) 279  
© The Author(s) 2018  
Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/0003319718776796  
journals.sagepub.com/home/ang



## Keywords

in-stent restenosis, inflammation, oxidative stress

Li et al reported in their recent article entitled “Evaluation of Preprocedural Laboratory Parameters as Predictors of Drug-Eluting Stent Restenosis in Coronary Chronic Total Occlusion Lesions” that the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, low density lipoprotein cholesterol level, and stent length were independent risk factors for the development of in-stent restenosis (ISR) after drug-eluting stent implantation in patients who underwent successful percutaneous coronary intervention (PCI) for coronary chronic total occlusion lesions.<sup>1</sup>

Although interventional approaches and pharmacological therapies have improved, ISR remains a major problem in the stent era. It was reported that neointimal hyperplasia was triggered by stents, and ISR could result from several mechanisms including inflammation and oxidative stress.<sup>2-4</sup> In our recent study, we demonstrated that CHA<sub>2</sub>DS<sub>2</sub>-VASc (congestive heart failure, hypertension, age  $\geq 75$  years, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, age 65-74 years, female gender) score could be also used as a predictor of ISR.<sup>5</sup> We also found a significant positive correlation between CHA<sub>2</sub>DS<sub>2</sub>-VASc score and C-reactive protein levels.<sup>5</sup> However, Li et al<sup>1</sup> did not calculate the CHA<sub>2</sub>DS<sub>2</sub>-VASc score of the study population in their study. Moreover, Kocas et al<sup>6</sup> suggested that statin nonadherence in patients with PCI was associated with an increased risk of ISR. However, there is also no data regarding statin and other medication usage in the Li et al<sup>1</sup> study.

The present study findings must be interpreted in light of several confounding factors before making a definite decision about ISR in patients who underwent PCI.

## ORCID iD

Mehmet Kadri Akboga  <http://orcid.org/0000-0001-5498-2837>

Samet Yilmaz  <http://orcid.org/0000-0002-8445-1911>

## References

1. Li C, Shen Y, Xu R, et al. Evaluation of preprocedural laboratory parameters as predictors of drug-eluting stent restenosis in coronary chronic total occlusion lesions. *Angiology*. 2019;70(3):272-8.
2. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. *J Am Coll Cardiol*. 1998;31:224-30.
3. Yilmaz S, Akboga MK, Sen F, et al. Usefulness of the monocyte-to-high-density lipoprotein cholesterol ratio to predict bare metal stent restenosis. *Biomark Med*. 2016;10:959-66.
4. Akboga MK, Yalcin R, Sahinarslan A, et al. Effect of serum YKL-40 on coronary collateral development and SYNTAX score in stable coronary artery disease. *Int J Cardiol*. 2016;224:323-7.
5. Yilmaz S, Akboga MK, Aras D, Topaloglu S. Evaluation of the predictive value of CHA(2)DS(2)-VASc score for in-stent restenosis. *Angiology*. 2018;69:38-42.
6. Kocas C, Abaci O, Kocas BB, et al. Impact of statin non-adherence on in-stent restenosis following bare-metal stent implantation. *Int J Cardiol*. 2016;203:529-31.

<sup>1</sup> Department of Cardiology, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey

<sup>2</sup> Department of Cardiology, Pamukkale University Hospital, Denizli, Turkey

## Corresponding Author:

Samet Yilmaz, Department of Cardiology, Pamukkale University Hospital, Denizli, Turkey.

Email: sametyilmazmd@gmail.com